Sohini Das

All stories by Sohini Das

Cleaner Fuels Driving One-Fifth Of PVs Sold In India

Cleaner Fuels Driving One-Fifth Of PVs Sold In India

Rediff.com6 days ago

Auto manufacturers have focused on launching CNG variants of their popular models to meet consumer demand for vehicles with lower running costs.

'Second-gen promoters more open to selling out'

'Second-gen promoters more open to selling out'

Rediff.com6 Jun 2024

'There is not any negative connotation associated with it.'

'Depending on the product, the pricing pressure will always be there'

'Depending on the product, the pricing pressure will always be there'

Rediff.com3 Jun 2024

'That is a significant milestone for us and something we aspired for.'

New-Gen COVID Jabs Coming Soon...

New-Gen COVID Jabs Coming Soon...

Rediff.com28 May 2024

India currently does not have any XBB 1.5 variant-based vaccines available.

Should Govt Continue Covid Vax Drive?

Should Govt Continue Covid Vax Drive?

Rediff.com20 May 2024

India has covered enough population with vaccine and infection, but protein vaccines should remain available on payment basis for elderly and those with comorbidities.

M&M shifts to high gear with Rs 37K cr investments

M&M shifts to high gear with Rs 37K cr investments

Rediff.com17 May 2024

Automotive (auto) major Mahindra & Mahindra (M&M), which is readying to launch nine sport utility vehicles (internal combustion engine/ICE), seven Born Electric Vehicles (BEVs), and seven light commercial vehicles by 2030, has outlined an investment of Rs 27,000 crore in its auto business between 2024-25 (FY25) and 2026-27 (FY27). Over the next three years, the company will deploy Rs 37,000 crore, including its auto business, farm business (Rs 5,000 crore), and service business (Rs 5,000 crore).

Gut Health Key To Prevent Chronic Illnesses

Gut Health Key To Prevent Chronic Illnesses

Rediff.com24 Apr 2024

Maintaining the balance of gut microbiota is important as an imbalance, also known as dysbiosis, can cause or aggravate different diseases, including but not limited to digestive problems such as inflammatory bowel syndrome, mental health issues like anxiety and depression and menstrual problems.

Zydus gets China nod for kidney disease drug

Zydus gets China nod for kidney disease drug

Rediff.com24 Apr 2024

Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA). In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus. CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.

Nearly one in two luxury cars sold in March quarter was Mercedes Benz

Nearly one in two luxury cars sold in March quarter was Mercedes Benz

Rediff.com12 Apr 2024

Nearly one in two luxury cars sold in India in the first three months of 2024 was a Mercedes Benz, which achieved its best ever quarter (January-March), selling 5,412 units, up 15 per cent year-on-year (Y-o-Y) from 4,697 units in the previous year.

Why Drug Prices Won't Increase This Year

Why Drug Prices Won't Increase This Year

Rediff.com5 Apr 2024

The government has been stringent with pricing changes. Prices of 651 essential medicines came down from April 1, 2023 by 6.73 per cent with the government capping ceiling prices of these drugs.

Why Hospital Stays Are Getting Shorter

Why Hospital Stays Are Getting Shorter

Rediff.com3 Apr 2024

'Every hospital now tracks length of stay closely.' 'More efficiency is brought into the system now.'

Indian pharma companies bank on 'mother brands' to boost revenue growth

Indian pharma companies bank on 'mother brands' to boost revenue growth

Rediff.com28 Mar 2024

Indian pharma companies are focussing on flagship products or mother brands under which they launch various new combinations to ensure robust revenue growth as well as therapy leadership. An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales. Sheetal Sapale, vice-president, commercial at Pharmarack, said, "Mother brands are analogous to an aggressive player who has put in a lot of effort during the prime years of life but now continues to silently nurture the brand family to collectively cross newer benchmarks of success."

Skoda to drive in Brezza, Sonet rival in H1FY25

Skoda to drive in Brezza, Sonet rival in H1FY25

Rediff.com28 Feb 2024

koda Auto India is set to drive in a new car by the first half of next year to reach its target of 100,000 unit annual sales in the country by 2026. The compact sports utility vehicle (SUV) will be positioned against the likes of Maruti Brezza, Hyundai Venue, and Kia Sonet, and would be competitively priced, a senior company official said. koda will also export the car to right-hand-drive markets like Australia, New Zealand and the Asean nations.

GOOD News! No Drug Price Hike In 2024

GOOD News! No Drug Price Hike In 2024

Rediff.com6 Feb 2024

For the consumer, there would be practically no impact on prices of essential medicines this year.

Q3 result preview: US, India to aid revenue growth for Pharma Inc

Q3 result preview: US, India to aid revenue growth for Pharma Inc

Rediff.com30 Jan 2024

The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.

'Aster DM's plan is to be among top three in India'

'Aster DM's plan is to be among top three in India'

Rediff.com27 Jan 2024

'Now that we are a pure-play India business, many investors are open to investing.'

Fortis plans acquisitions, may opt for neutral brand name

Fortis plans acquisitions, may opt for neutral brand name

Rediff.com22 Jan 2024

Delhi-headquartered Fortis Healthcare is open to acquisition of hospitals with over 250-300 bed sizes as part of its strategy to grow at a faster clip. It may also opt for a neutral brand name soon. Neutral brand is a new brand, which is not owned by any of the stakeholders.

Domestic pharma market grew by 6.8% in 2023

Domestic pharma market grew by 6.8% in 2023

Rediff.com22 Jan 2024

The Indian pharmaceutical market (IPM) grew 6.8 per cent to touch a turnover of ~1.93 trillion in calendar year 2023, despite volumes going down marginally by 0.9 per cent. This indicates the price increase has been the major growth driver. Growth in the moving annual turnover (the previous 12 months' turnover) in December was 5.1 per cent and that in new product introduction 2.6 per cent, while volumes dipped 0.9 per cent, leading to an overall growth rate of 6.8 per cent, according to the data from market research firm Pharmatrac.

From Ashok Leyland to VECV, busmakers' sales entered the fast lane in 2023

From Ashok Leyland to VECV, busmakers' sales entered the fast lane in 2023

Rediff.com10 Jan 2024

The demand for buses largely remained robust in 2023, driven by the increasing need for public mobility and replacement. Ashok Leyland Limited (ALL) recorded a 64 per cent year-on-year increase in sales of medium and heavy commercial vehicle (MHCV) buses during the April-to-December period of 2023 to 11,216 units. Volvo Eicher Commercial Vehicles (VECV) posted 24.7 per cent sales growth between April and December for light and medium-duty buses, and 36.9 per cent growth for heavy-duty buses.

'APIs are a very strategic part of Biocon's business'

'APIs are a very strategic part of Biocon's business'

Rediff.com7 Jan 2024

'There is no reason why we should break this business up.'

Next